Opinion

Video

Impact of Emerging Therapies on Outcomes for EGFR-Mutated NSCLC

Alan Chin, PharmD, BCOP, examines the PALOMA-3 trial's influence on the treatment of EGFR-mutated metastatic NSCLC and explores the evolving role of antibody-drug conjugates (ADCs) in the therapeutic landscape of EGFR-mutated NSCLC.

  1. How might the advent of subcutaneous amivantamab, currently being studied in the PALOMA-3 trial, impact the treatment of EGFR-mutated metastatic NSCLC? What opportunities or challenges might this impose?
  2. How do you see the role of antibody-drug conjugates (ADCs) evolving in the treatment landscape of EGFR-mutated NSCLC, and are there any in the pipeline that you are particularly excited about?
Related Videos
3 KOLs are featured in this series.
3 KOLs are featured in this series.
3 KOLs are featured in this series.
3 KOLs are featured in this series.
TRUST-I and TRUST-II Trials Show Promising Results for Taletrectinib in ROS1+ NSCLC
3 KOLs are featured in this series.
3 KOLs are featured in this series.
WCLC, lung cancer, NSCLC
MARIPOSA Study: Long-Term Outcomes and Next Steps for Amivantamab Plus Lazertinib in EGFR-Mutant NSCLC
The EMPOWER-Lung 1 Trial: Five-Year Outcomes of Cemiplimab Monotherapy in Advanced NSCLC
Related Content
Close-up of tumor in lungs -- Image credit: Dr_Microbe | stock.adobe.com
October 23rd 2024

Current Targeted Therapy Options in ROS1-Positive NSCLC

Nicole Bentivegna, PharmD, BCOP
Pharmacy Focus: Oncology Edition- Benefits of Subcutaneous Amivantamab for Lung Cancer Treatment
June 27th 2024

Pharmacy Focus: Oncology Edition- Benefits of Subcutaneous Amivantamab for Lung Cancer Treatment

Emerging HER2-Targeted Therapies in NSCLC: Zongertinib and BAY 2927088
October 17th 2024

Emerging HER2-Targeted Therapies in NSCLC: Zongertinib and BAY 2927088

Shelby L Quinn, PharmD, BCOP
Pharmacy Focus: Oncology Edition- Latest Updates in Non-Small Cell Lung Cancer Treatment
February 26th 2024

Pharmacy Focus: Oncology Edition- Latest Updates in Non-Small Cell Lung Cancer Treatment

HER2-Targeted Treatments for NSCLC: Introducing Zongertinib
October 3rd 2024

HER2-Targeted Treatments for NSCLC: Introducing Zongertinib

Wiktoria Bogdanska, PharmD, BCOP
Image Credit: © Postmodern Studio - stock.adobe.com
Published: September 26th 2024 | Updated: September 26th 2024

FDA Approves Osimertinib for Unresectable EGFR-Mutated Lung Cancer

Alexandra Gerlach, Associate Editor